MCID: ANP006
MIFTS: 47

Anaplastic Ependymoma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Anaplastic Ependymoma

MalaCards integrated aliases for Anaplastic Ependymoma:

Name: Anaplastic Ependymoma 53 59 55 6 73
High-Grade Ependymoma 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic ependymoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251646
UMLS via Orphanet 74 C0280788
UMLS 73 C0280788

Summaries for Anaplastic Ependymoma

NIH Rare Diseases : 53 Anaplastic ependymoma is a type of ependymoma, which is a tumor that forms when cells in the central nervous system (including the brain and spinal cord) begin to multiply rapidly. An ependymoma is anaplastic if the cells grow very quickly and are significantly unusual in shape. Ependymomas can occur at any age. When ependymomas occur in children, they are more frequently located in the brain (intracranial). Ependymomas are more often found in the spinal cord of affected adults. Symptoms of an anaplastic ependymoma depend on the age of the person and the size and location of the tumor but may include headaches, nausea, vision changes, seizures, and changes in mood or personality.  The exact cause of an anaplastic ependymoma is not known, but it is thought that certain changes (acquired pathogenic variants, also known as somatic mutations ) in specific genes in some cells of the body allow the cells to begin growing quickly. A diagnosis of anaplastic ependymoma is generally suspected based on imaging with MRI or CT scan. The diagnosis can be confirmed with a biopsy of the tumor or when the tumor is removed (resected). Treatment for anaplastic ependymoma begins with surgery to remove as much of the tumor as possible. Radiation therapy is also recommended for people with anaplastic ependymoma.

MalaCards based summary : Anaplastic Ependymoma, also known as high-grade ependymoma, is related to subependymoma and malignant ependymoma, and has symptoms including headache, nausea and seizures. An important gene associated with Anaplastic Ependymoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Neuroscience and Epstein-Barr virus infection. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are behavior/neurological and normal

Related Diseases for Anaplastic Ependymoma

Diseases related to Anaplastic Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 subependymoma 32.3 GFAP SYP
2 malignant ependymoma 31.3 GFAP NF2 RELA
3 ependymoblastoma 30.2 GFAP VIM
4 ganglioglioma 29.8 GFAP S100B SYP
5 ependymoma 29.4 GFAP MUC1 NF2 RELA S100B SYP
6 myxopapillary ependymoma 29.2 GFAP MUC1 S100B VIM
7 angiocentric glioma 29.1 GFAP S100B SYP VIM
8 hydrocephalus 28.8 GFAP PTEN SYP
9 gliosarcoma 28.3 GFAP PTEN S100B VIM
10 malignant adult ependymoma 11.1
11 moyamoya disease 2 10.9 LOC100294362 RNF213
12 localized hypertrophic neuropathy 10.8 MUC1 S100B
13 sclerosing perineurioma 10.8 MUC1 S100B
14 reticular perineurioma 10.8 MUC1 S100B
15 non-functioning pituitary adenoma 10.7 MUC1 S100B
16 epithelioid malignant peripheral nerve sheath tumor 10.7 MUC1 S100B
17 sinonasal undifferentiated carcinoma 10.7 MUC1 SYP
18 aggressive digital papillary adenocarcinoma 10.7 MUC1 S100B
19 middle ear adenoma 10.7 MUC1 SYP
20 ovarian small cell carcinoma 10.7 MUC1 SYP
21 hypoganglionosis 10.7 S100B SYP
22 rosette-forming glioneuronal tumor 10.6 S100B SYP
23 myopericytoma 10.6 RELA S100B
24 mucinous ovarian cystadenoma 10.6 MUC1 SYP
25 supratentorial primitive neuroectodermal tumor 10.6 S100B SYP
26 ampulla of vater neoplasm 10.6 MUC1 SYP
27 malignant mixed mullerian tumor 10.6 MUC1 VIM
28 bednar tumor 10.6 S100B VIM
29 nodular hidradenoma 10.6 MUC1 VIM
30 endometrial mucinous adenocarcinoma 10.6 MUC1 VIM
31 biphasic synovial sarcoma 10.6 MUC1 VIM
32 functioning pituitary adenoma 10.6 MUC1 S100B
33 adenofibroma 10.6 MUC1 VIM
34 sclerosing hemangioma 10.5 MUC1 SYP
35 cutaneous leiomyosarcoma 10.5 GFAP MUC1
36 meningeal melanocytoma 10.5 MUC1 S100B
37 hidradenoma 10.5 MUC1 VIM
38 reticulum cell sarcoma 10.5 MUC1 VIM
39 clear cell meningioma 10.5 GFAP MUC1
40 juvenile xanthogranuloma 10.5 S100B VIM
41 desmoplastic infantile ganglioglioma 10.5 GFAP SYP
42 mucinous cystadenocarcinoma 10.5 MUC1 VIM
43 extraventricular neurocytoma 10.5 GFAP SYP
44 mesenchymal chondrosarcoma 10.5 MUC1 VIM
45 lung combined type small cell carcinoma 10.5 GFAP SYP
46 cutaneous fibrous histiocytoma 10.5 S100B VIM
47 pilomyxoid astrocytoma 10.5 GFAP SYP
48 dermoid cyst 10.5 MUC1 VIM
49 central nervous system primitive neuroectodermal neoplasm 10.4 GFAP SYP
50 olfactory neuroblastoma 10.4 S100B SYP

Graphical network of the top 20 diseases related to Anaplastic Ependymoma:



Diseases related to Anaplastic Ependymoma

Symptoms & Phenotypes for Anaplastic Ependymoma

UMLS symptoms related to Anaplastic Ependymoma:


headache, nausea, seizures, vomiting

MGI Mouse Phenotypes related to Anaplastic Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 S100B SYP VIM GFAP MDM2 NF2
2 normal MP:0002873 9.17 S100B SYP GFAP MDM2 PTEN RELA

Drugs & Therapeutics for Anaplastic Ependymoma

Drugs for Anaplastic Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
7 Analgesics Phase 3,Phase 2,Phase 1
8 Adjuvants, Anesthesia Phase 3
9 Central Nervous System Stimulants Phase 3,Phase 2
10 Cholinergic Agents Phase 3,Phase 2
11 Cholinesterase Inhibitors Phase 3,Phase 2
12 Narcotics Phase 3
13 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Nootropic Agents Phase 3,Phase 2
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Dopamine Agents Phase 3,Not Applicable
22 Neurotransmitter Uptake Inhibitors Phase 3
23 Dexmethylphenidate Hydrochloride Phase 3
24 Dopamine Uptake Inhibitors Phase 3
25 Cola Nutraceutical Phase 3,Phase 1
26
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Ethanol Approved Phase 1, Phase 2 64-17-5 702
29
Carmustine Approved, Investigational Phase 1, Phase 2,Phase 2 154-93-8 2578
30
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
35
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
36
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
37
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
38
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
39
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
40
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
41
Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
42 Piracetam Approved, Investigational Phase 2 7491-74-9
43
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Tamoxifen Approved Phase 2 10540-29-1 2733526
46
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
47
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
48
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Armodafinil Approved, Investigational Phase 2 112111-43-0

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
5 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
6 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
7 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
8 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
9 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
10 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
11 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
12 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
13 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
14 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
15 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
16 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
17 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
18 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
19 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
20 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
21 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
22 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
23 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
24 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
25 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
26 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
27 Everolimus for Children With Recurrent or Progressive Ependymoma Recruiting NCT02155920 Phase 2 Everolimus
28 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Active, not recruiting NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
29 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting NCT01478321 Phase 2 Temozolomide
30 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
31 Antineoplaston Therapy in Treating Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
32 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
33 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors Withdrawn NCT00243490 Phase 2
34 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
35 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
36 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
37 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
38 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Gluco Completed NCT01082926 Phase 1
39 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
40 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
41 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
42 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
43 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Completed NCT01480050 Phase 1 temozolomide;Mibefradil
44 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
45 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
46 Carmustine in Treating Patients With Recurrent Malignant Glioma Completed NCT00004028 Phase 1 carmustine
47 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
48 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
49 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
50 Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib

Search NIH Clinical Center for Anaplastic Ependymoma

Genetic Tests for Anaplastic Ependymoma

Anatomical Context for Anaplastic Ependymoma

MalaCards organs/tissues related to Anaplastic Ependymoma:

41
Brain, Spinal Cord, Bone, Bone Marrow, Liver, T Cells, Kidney

Publications for Anaplastic Ependymoma

Articles related to Anaplastic Ependymoma:

(show top 50) (show all 99)
# Title Authors Year
1
Adult Supratentorial Extraventricular Anaplastic Ependymoma: Therapeutic Approach and Clinical Review. ( 29492136 )
2018
2
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
3
Radiation necrosis following proton therapy successfully treated by low-dose bevacizumab in a patient with relapsed anaplastic ependymoma. ( 29667785 )
2018
4
Pediatric Isolated Cortical (Ectopic) Anaplastic Ependymoma. ( 29492147 )
2018
5
Rapid autopsy of a patient with recurrent anaplastic ependymoma. ( 28942746 )
2017
6
Multifocal intradural extramedullary anaplastic ependymoma of the spine. ( 29354756 )
2017
7
Anaplastic Ependymoma With Ganglionic Differentiation: Report of a Rare Case and Implications in Diagnosis. ( 28554236 )
2017
8
Spinal cord anaplastic ependymoma induced by radiation treatment of breast cancer. ( 28555490 )
2017
9
"Drop" Metastases from an Operated Case of Intracranial Anaplastic Ependymoma Identified on Fluoro-2-deoxyglucose Positron Emission Tomography/Computed Tomography. ( 28242994 )
2017
10
Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. ( 28831588 )
2017
11
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. ( 28393092 )
2017
12
Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy. ( 26682738 )
2016
13
Radiation-induced anaplastic ependymoma mimicking a skull base meningioma: A case report. ( 26893630 )
2016
14
Pure extra-axial supratentorial anaplastic ependymoma with no cortical attachment: A rare case. ( 26954823 )
2016
15
Supratentorial extraventricular WHO grade III (anaplastic) ependymoma 17 years after total removal of WHO grade II ependymoma of the fourth ventricle. ( 27215793 )
2016
16
Magnetic resonance imaging findings of extraventricular anaplastic ependymoma: A report of 11 cases. ( 27602137 )
2016
17
Brain Tumor in an In Vitro Fertilization-Facilitated Pregnancy: Fourth Ventricle Anaplastic Ependymoma in the Second Trimester. ( 27330925 )
2016
18
Angiocentric glioma transformed into anaplastic ependymoma: Review of the evidence for malignant potential. ( 27742374 )
2016
19
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma With Low MGMT Protein Expression. ( 26305586 )
2015
20
An extraneural primary anaplastic ependymoma at the subcutaneous inguinal region: Report of a rare case. ( 26549094 )
2015
21
Paediatric Intracranial Anaplastic Ependymoma: The Role of Multiple Surgical Resections for Disease Relapse in Maintaining Quality of Life and Prolonged Survival. ( 25871983 )
2015
22
Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. ( 25455735 )
2015
23
Anaplastic ependymoma of spinal cord presented with lower back pain. ( 25843250 )
2015
24
Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy. ( 26488903 )
2015
25
Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. ( 26251808 )
2015
26
An 11 Year Old Child with a Right Parieto-Occipital Lesion. Anaplastic Ependymoma (WHO Grade III) with Granular Cell Features. ( 26086056 )
2015
27
Supratentorial Extraventricular Anaplastic Ependymoma Presenting with Repeated Intratumoral Hemorrhage. ( 25408930 )
2014
28
Anaplastic ependymoma of the third ventricle. ( 24643478 )
2014
29
Treatment of Ovarian Anaplastic Ependymoma by an Aromatase Inhibitor. ( 24413241 )
2014
30
Ectopic cortical anaplastic ependymoma: an unusual case report and literature review. ( 25051164 )
2014
31
Supratentorial extraventricular anaplastic ependymoma in a child. ( 24623545 )
2014
32
Anaplastic ependymoma with holocordal and intracranial meningeal carcinomatosis and holospinal bone metastases. ( 23422903 )
2013
33
Extra and intramedullary anaplastic ependymoma in thoracic spinal cord. ( 24757483 )
2013
34
Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. ( 24085643 )
2013
35
Cortical anaplastic ependymoma with significant desmoplasia: a case report and literature review. ( 24455359 )
2013
36
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( 24192541 )
2013
37
Anaplastic ependymoma with ependymoblastic multilayered rosettes. ( 23791209 )
2013
38
A headache presenting in the emergency room, a clinical manifestation of an unfortunate diagnosis (grade III left frontal anaplastic ependymoma with 1p deletion). ( 23912654 )
2013
39
Supratentorial extraventricular anaplastic ependymoma in an adult with repeated intratumoral hemorrhage. ( 23546851 )
2013
40
Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: a case report. ( 23163298 )
2013
41
Cystic with mural nodule: Unusual radiological presentation of supratentorial anaplastic ependymoma. ( 23248684 )
2012
42
Supratentorial extra-axial anaplastic ependymoma mimicking a meningioma. ( 22406799 )
2012
43
Purely cortical anaplastic ependymoma. ( 23119204 )
2012
44
Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. ( 22081297 )
2012
45
Sacrococcygeal myxopapillary ependymoma with anaplastic ependymoma component in an infant. ( 23560014 )
2012
46
An anaplastic ependymoma presenting as an intrinsic brainstem glioma. ( 22406810 )
2012
47
Anaplastic ependymoma simulating glioblastoma in the cerebrum of an adult. ( 21833575 )
2012
48
Metronomic cyclophosphamide with cisplatin and bevacizumab: a new chemotherapeutic regimen for refractory anaplastic ependymoma. ( 23155280 )
2012
49
Metachronous occurrence of a temporal ganglioglioma and a bifrontal anaplastic ependymoma: coincidence or an explainable pathological curiosity? ( 21501061 )
2011
50
Isolated extracranial recurrence of anaplastic ependymoma. ( 20830772 )
2011

Variations for Anaplastic Ependymoma

ClinVar genetic disease variations for Anaplastic Ependymoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 RNF213 NM_001256071.2(RNF213): c.12841C> T (p.Arg4281Trp) single nucleotide variant other rs765980348 GRCh37 Chromosome 17, 78346864: 78346864
2 RNF213 NM_001256071.2(RNF213): c.12841C> T (p.Arg4281Trp) single nucleotide variant other rs765980348 GRCh38 Chromosome 17, 80373064: 80373064

Expression for Anaplastic Ependymoma

Search GEO for disease gene expression data for Anaplastic Ependymoma.

Pathways for Anaplastic Ependymoma

GO Terms for Anaplastic Ependymoma

Cellular components related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.92 NF2 PTEN SYP VIM

Biological processes related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.78 MDM2 PTEN RELA S100B
2 cellular response to hypoxia GO:0071456 9.5 MDM2 PTEN S100B
3 response to morphine GO:0043278 9.49 MDM2 RELA
4 regulation of neuronal synaptic plasticity GO:0048168 9.46 S100B SYP
5 astrocyte development GO:0014002 9.43 GFAP VIM
6 intermediate filament organization GO:0045109 9.4 GFAP VIM
7 response to inorganic substance GO:0010035 9.37 PTEN RELA
8 negative regulation of neuron projection development GO:0010977 9.33 GFAP MDM2 VIM
9 Bergmann glial cell differentiation GO:0060020 9.26 GFAP VIM
10 long-term synaptic potentiation GO:0060291 9.13 GFAP PTEN S100B
11 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Molecular functions related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 GFAP MDM2 PTEN RELA S100B SYP

Sources for Anaplastic Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....